Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis. - Wikidata - awgldk - TriplyDB

Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.

Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.

http://www.wikidata.org/entity/Q37375398

about

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy Comparative effectiveness of HIV testing and treatment in highly endemic regions.Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial Mortality along the continuum of HIV care in Rwanda: a model-based analysis.Economic evaluation of ART in resource-limited countries.The state of health economic research in South Africa: a systematic review.

P2860

Q24234853-CEF93EF8-47F6-46E0-AD87-4F58608810D8 Q34064269-2F9C743D-63EA-483F-95CB-D11A3E897415 Q34353431-EAF88AF0-134F-474B-9644-2D8325BEC9C2 Q34768650-58AD8FC7-0726-441D-A264-C27C95D18679 Q35214966-E3F1AACF-4105-4710-BCFA-519037712232 Q35854983-98A17BFF-5D79-4055-BD55-B518B4DE88A0 Q36179320-D10BA7B9-AE9A-4EE4-89C8-AF158D2D89A8 Q36209055-869C46C1-F17D-41B4-BAFC-6350FEB9777D Q37503832-631ACD51-48DB-4164-8895-B7EDE42B19F9 Q38027235-7F6B14D2-3F49-40B2-8810-0C03E4053CCC

P2860

Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.

http://www.wikidata.org/entity/Q37375398

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Expanding antiretroviral optio ...... a cost-effectiveness analysis.

@en

Expanding antiretroviral optio ...... a cost-effectiveness analysis.

@nl

type

label

Expanding antiretroviral optio ...... a cost-effectiveness analysis.

@en

Expanding antiretroviral optio ...... a cost-effectiveness analysis.

@nl

prefLabel

Expanding antiretroviral optio ...... a cost-effectiveness analysis.

@en

Expanding antiretroviral optio ...... a cost-effectiveness analysis.

@nl

P1433

Q37375398-CC845EB6-1A5C-415F-B584-C52963E720C3

P1476

Q37375398-7065561B-05A5-410F-ACC0-AA449E811582

P2093

Q37375398-12A28C21-B477-406B-B9D0-710C7089C7C7

Q37375398-74AFAB0A-2771-412C-A179-9582B78FB067

Q37375398-89042F6E-6355-457F-8808-7FF024FE61E6

Q37375398-9D7C3B3A-0158-4EDB-AF76-8496B757E1D7

Q37375398-DE7877FA-7C8D-4EC2-B57A-97EC94F3DFA5

P2860

Q37375398-04098D63-5C48-4802-9918-102ACF122030

Q37375398-06276225-5B03-414F-AE5B-71FD38170403

Q37375398-114F2FB7-A318-4C36-8976-F93204FF6CCF

Q37375398-1334C72E-16FD-474B-AD3D-A1975E8AC0DD

Q37375398-1435BDF1-62F7-484B-A448-511D18E3FF55

Q37375398-1FF0D957-51B8-4229-B15E-B8860C7E499D

Q37375398-1FFBE8D3-1741-44EE-AF3C-75D9077D3594

Q37375398-26D184DF-0521-4A88-BDA5-D4E35168A0E5

Q37375398-2C9AA4F2-0B6A-430B-B12E-C8CF7D4CAAE4

Q37375398-3192EFED-CEBF-4769-B953-B963D6E3BCEF

P304

Q37375398-F708358B-061D-48E2-BF66-9FC72CA93748

P31

Q37375398-7A7E5B8D-4F20-4DC1-A303-B4D88D19A7DE

P356

Q37375398-D3A66B42-7C2D-4817-B96F-2B409FA6BA04

P407

Q37375398-C7128A04-89CA-4902-827F-AA4C18E97819

P433

Q37375398-658A763C-D7B3-4CCF-84C7-7CC2DA4A09F9

P478

Q37375398-FC4D9F0C-9D98-4B79-8CE8-4ADCF8193B15

P577

Q37375398-722934C7-6A87-4EBD-A34A-0800315657B2

P5875

Q37375398-0A5BEFD1-DC9E-409C-9AD9-28D620EC5E4B

P698

Q37375398-A9B52103-738E-47CB-B1BB-74970AE7A5C8

P921

Q37375398-C5FD39DC-0A27-4EDD-80E0-444F1D3212BA

P932

Q37375398-7DB7F9B9-F11C-468E-BF27-1F0E0083CF14

P356

QAI.0B013E3181A4F9C4

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Expanding antiretroviral optio ...... a cost-effectiveness analysis.

@en

P2093

Ahmed M Bayoumi

http://www.w3.org/2001/XMLSchema#string

David A Katzenstein

http://www.w3.org/2001/XMLSchema#string

Douglas K Owens

http://www.w3.org/2001/XMLSchema#string

Eran Bendavid

http://www.w3.org/2001/XMLSchema#string

Robin Wood

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

Cost-effectiveness of highly active antiretroviral therapy in South Africa.

The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting

Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa.

Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis

Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

P304

106-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E3181A4F9C4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24433439

http://www.w3.org/2001/XMLSchema#string

P698

19448557

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2757100

http://www.w3.org/2001/XMLSchema#string